- Home
- FINW vs DMAC Comparison
FINW vs DMAC Comparison
Compare FINW & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- DMAC
- Stock Information
- Founded
- FINW 1999
- DMAC 2000
- Country
- FINW United States
- DMAC United States
- Employees
- FINW N/A
- DMAC N/A
- Industry
- FINW Commercial Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- DMAC Health Care
- Exchange
- FINW Nasdaq
- DMAC Nasdaq
- Market Cap
- FINW 261.6M
- DMAC 310.1M
- IPO Year
- FINW 2021
- DMAC N/A
- Fundamental
- Price
- FINW $19.27
- DMAC $7.09
- Analyst Decision
- FINW Buy
- DMAC Strong Buy
- Analyst Count
- FINW 4
- DMAC 3
- Target Price
- FINW $20.75
- DMAC $12.33
- AVG Volume (30 Days)
- FINW 11.7K
- DMAC 430.9K
- Earning Date
- FINW 10-23-2025
- DMAC 11-12-2025
- Dividend Yield
- FINW N/A
- DMAC N/A
- EPS Growth
- FINW N/A
- DMAC N/A
- EPS
- FINW 0.96
- DMAC N/A
- Revenue
- FINW $74,999,000.00
- DMAC N/A
- Revenue This Year
- FINW $52.89
- DMAC N/A
- Revenue Next Year
- FINW $20.66
- DMAC N/A
- P/E Ratio
- FINW $19.54
- DMAC N/A
- Revenue Growth
- FINW 10.21
- DMAC N/A
- 52 Week Low
- FINW $13.49
- DMAC $3.19
- 52 Week High
- FINW $20.94
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- FINW 56.14
- DMAC 68.97
- Support Level
- FINW $19.00
- DMAC $6.83
- Resistance Level
- FINW $19.80
- DMAC $7.46
- Average True Range (ATR)
- FINW 0.58
- DMAC 0.41
- MACD
- FINW -0.09
- DMAC 0.11
- Stochastic Oscillator
- FINW 59.23
- DMAC 82.98
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.